Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
BPC-157 Arginate (Stable Form)
BPC-157 Arginine Salt, BPC-157-Arg
The arginine salt form of BPC-157, developed to improve stability and shelf life compared to the standard acetate salt. BPC-157 arginate maintains the same gastric pentadecapeptide sequence but uses arginine as the counter-ion, which provides better stability at room temperature and in solution. This form is increasingly preferred by compounding pharmacies and researchers.
A synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in tissue repair and regeneration. Widely used in the biohacking community for injury recovery.
Same mechanism as standard BPC-157 — upregulates growth factor expression (VEGF, FGF, EGF), promotes angiogenesis, modulates nitric oxide pathways, and interacts with the dopaminergic system. The arginine counter-ion does not change the peptide's pharmacological activity but improves chemical stability, particularly in aqueous solution.
Promotes cell migration, blood vessel formation, and reduces inflammation. Upregulates actin, a cell-building protein critical for healing and cell migration to injury sites.
- Gut healing and GI repair
- Tendon and ligament recovery
- Muscle injury repair
- Neuroprotection
- Stable alternative to BPC-157 acetate
- Muscle and tendon repair
- Wound healing
- Reducing inflammation
- Hair regrowth (emerging research)
- Cardiac tissue repair
- Same risk profile as standard BPC-157
- No FDA-approved human trials
- Theoretical concerns about growth factor upregulation
- Quality varies between sources
- Limited human clinical data
- Potential tumor growth concerns (theoretical)
- Injection site reactions
- Headaches reported anecdotally
Same regulatory status as BPC-157. Removed from Category 2 on April 15, 2026. Scheduled for PCAC review on July 23, 2026 (Day 1). The arginate form is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.
PCAC: July 23, 2026
On April 15, 2026, the FDA announced TB-500 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 to determine eligibility for the 503A bulk drug substances list. Compounding pharmacies should exercise caution until PCAC takes action.
PCAC: July 23, 2026
- Thymosin β4 promotes dermal healing
2007 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.